Teaneck-based Phibro Animal Health Corp. on Tuesday said Glenn David will assume the role of chief financial officer. Richard Johnson, who has been serving as Phibro’s interim CFO since September 2023, will continue with Phibro for a period of time in an advisory capacity to ensure a smooth transition with his successor.
David brings over 30 years of experience in commercial and financial leadership roles. David’s most recent role was executive vice president and group president, U.S. operations, diagnostics, biodevices and insurance at Zoetis Inc. Prior to that, he served as executive vice president and group president, international operations, aquaculture, biodevices and insurance at Zoetis.
David was the CFO at Zoetis from 2016-2021, where he maintained a well-capitalized and financially disciplined business, creating significant value for shareholders, and, earlier in his career, he served as senior vice president of finance operations for Zoetis during its initial public offering in 2013.
Before the Zoetis IPO, David served in various financial roles at Pfizer Inc., including vice president of global finance for Pfizer Animal Health and vice president of finance for the U.S. Primary Care franchise.
“I am very excited to welcome Glenn to Phibro. Glenn brings a wealth of knowledge and experience, not only in financial matters, but in the animal health industry, which will be beneficial for Phibro as we continue to grow our business and bring value to our shareholders. He brings the skills and experience needed to play a key role in Phibro’s future success,” Jack Bendheim, Phibro’s chairman, CEO and president, said. “I also want to thank Dick Johnson, who previously served as Phibro’s chief financial officer for more than 18 years, for leading us through this transition period and for his help in ensuring the continued success of our business.”
